Twenty-six Thai HIV-infected children, aged 2 years or less were prospectively enrolled to receive non-nucleoside reverse transcription inhibitor-based highly active antiretroviral therapy (HAART). Twenty-two children (85%) had World Health Organization clinical stage 3 or 4. The median baseline CD4 cell percentage and plasma HIV RNA were 17% and 5.9 log 10 copies/mL, respectively. The median age at HAART initiation was 9.8 months (range, 1.5–24.0). One child died. The mean CD4 cell percentages at 24, 48, and 96 weeks of treatment were 26%, 31%, and 37%, respectively. The proportions of children with virologic suppression (<400 copies/mL) at week 24 and 48 were 14/26 (54%) and 19/26 (73%), respectively. Non-nucleoside reverse transcription inhibitor-based HAART is safe and effective in HIV-infected young children in a resource-limited setting.
From the *Research Institute for Health Sciences, and †Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Accepted for publication September 15, 2008.
Supported by the Thailand Research Fund of the Thai Government.
Address for correspondence: Virat Sirisanthana, MD, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand 50200. E-mail: email@example.com.